KPTI

Karyopharm

--(--)

Market Open: --

--(--)

Post-Market: --

Signals Analysis

Buy signal 1

Sell signal 2

consensus rating "Buy"

EPS Below Expectations

Revenue Below Expectations

Key Stats

--DAY`S RANGE--

--52 WK RANGE--

Open

Prev.Close

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

Low

52 Week High

52 Week Low

About KPTI

Karyopharm Therapeutics Inc.

A commercial-stage pharmaceutical company pioneering novel cancer therapies

Industry

Biological Technology

Established Date

12/22/2008

Listing Date

11/06/2013

Exchange

NASDAQ Stock Exchange

Full-time Employees

279

Fiscal Year Ends

12-31

Website

www.karyopharm.com

Security Type

Common stock

Office address

85 Wells Avenue, 2nd Floor, Newton, Massachusetts 02459

Business

Introduction

Karyopharm Therapeutics Inc., was incorporated in Delaware on December 22, 2008. The company is a clinical-stage pharmaceutical company focused on the discovery and development of novel first-line drugs targeting nuclear transport targets for the treatment of cancer and critical diseases. The company's scientific expertise focuses on understanding the regulation of intracellular transport between the nucleus and cytoplasm. The company discovers and develops wholly-owned, novel, small molecule, nuclear export selective inhibitor or SINE compounds that inhibit the nuclear export protein XPO 1. The company's lead drug candidate, Selinexor (KPT-330), an XPO 1 inhibitor, is being evaluated in multiple open-label Phase 1 clinical trials in patients with advanced pretreatment of relapsed and refractory hematologic and solid tumor malignancies.

Company Financials

EPS

KPTI has released its 2024 Q4 earnings. EPS was reported at -0.24, versus the expected -0.27, beating expectations. The chart below visualizes how KPTI has performed over recent quarters, highlighting trends in earnings surprises.

Revenue & Expenses

KPTI has released its 2024 Q4 earnings report, with revenue of 30.54M, reflecting a YoY change of -9.50%, and net profit of -30.78M, showing a YoY change of 26.43%. The Sankey diagram below clearly presents KPTI’s revenue sources and cost distribution.